Skip to main content

SISTEMA DE AYUDA A LA DECISION VALIDADO CLINICAMENTE BASADO EN MODELOS DE INTELIGENCIA ARTIFICIAL A NIVEL DE PIXEL PARA DECIDIR OPCIONES TERAPEUTICAS EN GLIOBLASTOMA

PID2019-104978RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT POLITÈCNICA DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unlocking Bevacizumab's Potential, rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients

  • Álvarez-Torres, María del Mar
  • Balañá, Carmen|||0000-0003-0771-0390
  • Fuster-Garcia, Elies|||0000-0002-0716-8960
  • Puig, Josep|||0000-0003-2791-6599
  • García Gómez, Juan Miguel|||0000-0002-3851-1557
Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels

  • Álvarez-Torres, María del Mar
  • López-Cerdán, Adolfo
  • Andreu, Zoraida
  • DE LA IGLESIA VAYÁ, MARIA DE LOS DESAMPARADOS
  • Fuster García, Elíes|||0000-0002-0716-8960
  • García García, Francisco|||0000-0003-1488-2764
  • Garcia-Gomez, Juan M
[EN] Global agreement in central nervous system (CNS) tumor classification is essential for predicting patient prognosis and determining the correct course of treatment, as well as for stratifying patients for clinical trials at international level. The last update by the World Health Organization of CNS tumor classification and grading in 2021 considered, for the first time, IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 as different tumors. Mutations in the genes isocitrate dehydrogenase (IDH) 1 and 2 occur early and, importantly, contribute to gliomagenesis. IDH mutation produces a metabolic reprogramming of tumor cells, thus affecting the processes of hypoxia and vascularity, resulting in a clear advantage for those patients who present with IDH-mutated astrocytomas. Despite the clinical relevance of IDH mutation, current protocols do not include full sequencing for every patient. Alternative biomarkers could be useful and complementary to obtain a more reliable classification. In this sense, magnetic resonance imaging (MRI)-perfusion biomarkers, such as relative cerebral blood volume and flow, could be useful from the moment of presurgery, without incurring additional financial costs or requiring extra effort. The main purpose of this work is to analyze the vascular and hemodynamic differences between IDH-wildtype glioblastoma and IDH-mutant astrocytoma. To achieve this, we evaluate and validate the association between dynamic susceptibility contrast-MRI perfusion biomarkers and IDH mutation status. In addition, to gain a deeper understanding of the vascular differences in astrocytomas depending on the IDH mutation, we analyze the transcriptomic bases of the vascular differences., This study was funded by: Grant PID2019-104978RB-I00/AEI/10.13039/501100011033 (ALBATROSS) funded by MCIN/AEI/ 10.13039/501100011033, Grant PID2021-127110OA-I00 (PROGRESS) funded by MCIN/AEI/10.13039/501100011033 (both from Agencia de Investigacion de Espana) and by ERDF A way of making Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Two-dimensional compact-finite-difference schemes for solving the bi-Laplacian operator with homogeneous wall-normal derivatives

  • Amo-Navarro, Jesús
  • Vinuesa, Ricardo
  • Conejero, J. Alberto|||0000-0003-3681-7533
  • Hoyas, Sergio|||0000-0002-8458-7288
[EN] In fluid mechanics, the bi-Laplacian operator with Neumann homogeneous boundary conditions emerges when transforming the Navier-Stokes equations to the vorticity-velocity formulation. In the case of problems with a periodic direction, the problem can be transformed into multiple, independent, two-dimensional fourth-order elliptic problems. An efficient method to solve these two-dimensional bi-Laplacian operators with Neumann homogeneus boundary conditions was designed and validated using 2D compact finite difference schemes. The solution is formulated as a linear combination of auxiliary solutions, as many as the number of points on the boundary, a method that was prohibitive some years ago due to the large memory requirements to store all these auxiliary functions. The validation has been made for different field configurations, grid sizes, and stencils of the numerical scheme, showing its potential to tackle high gradient fields as those that can be found in turbulent flows., This work was supported by RTI2018-102256-B-I00 of MINECO/FEDER and the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Efficient recurrent neural network methods for anomalously diffusing single particle short and noisy trajectories

  • Garibo i Orts, Óscar
  • Baeza-Bosca, Alba
  • Garcia March, Miguel Angel|||0000-0001-7092-838X
  • Conejero, J. Alberto|||0000-0003-3681-7533
[EN] Anomalous diffusion occurs at very different scales in nature, from atomic systems to motions in cell organelles, biological tissues or ecology, and also in artificial materials, such as cement. Being able to accurately measure the anomalous exponent associated to a given particle trajectory, thus determining whether the particle subdiffuses, superdiffuses or performs normal diffusion, is of key importance to understand the diffusion process. Also it is often important to trustingly identify the model behind the trajectory, as it this gives a large amount of information on the system dynamics. Both aspects are particularly difficult when the input data are short and noisy trajectories. It is even more difficult if one cannot guarantee that the trajectories output in experiments are homogeneous, hindering the statistical methods based on ensembles of trajectories. We present a data-driven method able to infer the anomalous exponent and to identify the type of anomalous diffusion process behind single, noisy and short trajectories, with good accuracy. This model was used in our participation in the anomalous diffusion (AnDi) challenge. A combination of convolutional and recurrent neural networks was used to achieve state-of-the-art results when compared to methods participating in the AnDi challenge, ranking top 4 in both classification and diffusion exponent regression, JAC acknowledges support from ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00). MAGM acknowledges funding from the Spanish Ministry of Education and Vocational Training (MEFP) through the Beatriz Galindo program 2018 (BEAGAL18/00203) and Spanish Ministry MINECO (FIDEUA PID2019-106901GBI00/10.13039/501100011033)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Unlocking Bevacizumab&apos, s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients

  • Alvarez-Torres, Maria del Mar
  • Balaña, Carmen
  • Puig, Josep
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Garcia-Gomez, Juan M
[EN] Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment., M.Á-T was supported by DPI2016-80054-R (Programa Estatal de Promoción del Talento y su Empleabilidad en I + D + i). This work was partially supported by the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017 2020, No. PID2019-104978RB-I00). This study was partially funded by the Fundació La Marató TV3 (665/C/2013). Grant PID2021- 127110OA-I00 (PROGRESS) was funded by MCIN/AEI/10.13039/501100011033 and ERDF, a way of making Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification

  • Álvarez-Torres, María del Mar
  • Juan-Albarracín, Javier
  • Reynes, Gaspar
  • Aparici-Robles, Fernando
  • Ferrer Lozano, Jaime
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Garcia-Gomez, Juan M
[EN] Background The microvessels area (MVA), derived from microvascular proliferation, is a biomarker useful for high-grade glioma classification. Nevertheless, its measurement is costly, labor-intense, and invasive. Finding radiologic correlations with MVA could provide a complementary non-invasive approach without an extra cost and labor intensity and from the first stage. This study aims to correlate imaging markers, such as relative cerebral blood volume (rCBV), and local MVA in IDH-wildtype glioblastoma, and to propose this imaging marker as useful for astrocytoma grade 4 classification. Methods Data from 73 tissue blocks belonging to 17 IDH-wildtype glioblastomas and 7 blocks from 2 IDH-mutant astrocytomas were compiled from the Ivy GAP database. MRI processing and rCBV quantification were carried out using ONCOhabitats methodology. Histologic and MRI co-registration was done manually with experts' supervision, achieving an accuracy of 88.8% of overlay. Spearman's correlation was used to analyze the association between rCBV and microvessel area. Mann-Whitney test was used to study differences of rCBV between blocks with presence or absence of microvessels in IDH-wildtype glioblastoma, as well as to find differences with IDH-mutant astrocytoma samples. Results Significant positive correlations were found between rCBV and microvessel area in the IDH-wildtype blocks (p < 0.001), as well as significant differences in rCBV were found between blocks with microvascular proliferation and blocks without it (p < 0.0001). In addition, significant differences in rCBV were found between IDH-wildtype glioblastoma and IDH-mutant astrocytoma samples, being 2-2.5 times higher rCBV values in IDH-wildtype glioblastoma samples. Conclusions The proposed rCBV marker, calculated from diagnostic MRIs, can detect in IDH-wildtype glioblastoma those regions with microvessels from those without it, and it is significantly correlated with local microvessels area. In addition, the proposed rCBV marker can differentiate the IDH mutation status, providing a complementary non-invasive method for high-grade glioma classification., This work was funded by grants from the National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00) (JMGG); H2020-SC1-2016-CNECT Project (No. 727560) (JMGG), and H2020SC1-BHC-2018-2020 (No. 825750) (JMGG). M.A.T was supported by DPI201680054-R (Programa Estatal de Promocion del Talento y su Empleabilidad en I + D + i). EFG was supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 844646. The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

The prognostic relevance of a gene expression signature in MRI-defined highly vascularized glioblastoma

  • Montosa-Micó, Víctor
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Gómez-Mahiques, María
  • López-Mateu, Carlos
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Álvarez-Torres, María del Mar
  • Burgos-Panadero, Rebeca
[EN] Background The vascular heterogeneity of glioblastomas (GB) remains an important area of research, since tumor progression and patient prognosis are closely tied to this feature. With this study, we aim to identify gene expression profiles associated with MRI-defined tumor vascularity and to investigate its relationship with patient prognosis. Methods The study employed MRI parameters calculated with DSC Perfusion Quantification of ONCOhabitats glioma analysis software and RNA-seq data from the TCGA-GBM project dataset. In our study, we had a total of 147 RNA-seq samples, which 15 of them also had MRI parameter information. We analyzed the gene expression profiles associated with MRI-defined tumor vascularity using differential gene expression analysis and performed Log-rank tests to assess the correlation between the identified genes and patient prognosis. Results The findings of our research reveal a set of 21 overexpressed genes associated with the high vascularity pattern. Notably, several of these overexpressed genes have been previously implicated in worse prognosis based on existing literature. Our log-rank test further validates that the collective upregulation of these genes is indeed correlated with an unfavorable prognosis. This set of genes includes a variety of molecules, such as cytokines, receptors, ligands, and other molecules with diverse functions. Conclusions Our findings suggest that the set of 21 overexpressed genes in the High Vascularity group could potentially serve as prognostic markers for GB patients. These results highlight the importance of further investigating the relationship between the molecules such as cytokines or receptors underlying the vascularity in GB and its observation through MRI and developing targeted therapies for this aggressive disease., This work was funded by Grant PID2021-127110OA-I00 (PROGRESS) funded by MCIN/AEI/10.13039/501100011033 and by ERDF, Beca Margarita Salas funded by Ministerio de Ciencia, Innovacion y Universidades. Grant ID: MS21-046, SINUE (INNEST/2022/87 Agencia Valenciana de la Innovacion), ALBATROSS (PID2019-104978RB-I00), Programa INVESTIGO (INVEST/2022/298) and Grant CIAICO/2022/064 (Lalaby-Glio) funded by Generalitat Valenciana.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtype

  • Chelebian, Eduard
  • Álvarez-Torres, María del Mar
  • Juan-Albarracín, Javier
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Garcia-Gomez, Juan M
[EN] Background and purpose Genetic classifications are crucial for understanding the heterogeneity of glioblastoma. Recently, perfusion MRI techniques have demonstrated associations molecular alterations. In this work, we investigated whether perfusion markers within infiltrated peripheral edema were associated with proneural, mesenchymal, classical and neural subtypes. Materials and methods ONCOhabitats open web services were used to obtain the cerebral blood volume at the infiltrated peripheral edema for MRI studies of 50 glioblastoma patients from The Cancer Imaging Archive: TCGA-GBM. ANOVA and Kruskal-Wallis tests were carried out in order to assess the association between vascular features and the Verhaak subtypes. For assessing specific differences, Mann-Whitney U-test was conducted. Finally, the association of overall survival with molecular and vascular features was assessed using univariate and multivariate Cox models. Results ANOVA and Kruskal-Wallis tests for the maximum cerebral blood volume at the infiltrated peripheral edema between the four subclasses yielded false discovery rate corrected p-values of <0.001 and 0.02, respectively. This vascular feature was significantly higher (p = 0.0043) in proneural patients compared to the rest of the subtypes while conducting Mann-Whitney U-test. The multivariate Cox model pointed to redundant information provided by vascular features at the peripheral edema and proneural subtype when analyzing overall survival. Conclusions Higher relative cerebral blood volume at infiltrated peripheral edema is associated with proneural glioblastoma subtype suggesting underlying vascular behavior related to molecular composition in that area., This work was partially supported by: MTS4up project (National Plan for Scientific and Technical Research and Innovation 2013-2016, No. DPI2016-80054-R) (JMGG); H2020-SC1-2016CNECT Project (No. 727560) (JMGG), Fundacio Bancaria laCaixa (LCF/TR/CI16/10010016) and H2020-SC1-BHC-2018-2020 (No. 825750) (JMGG); PID2019-104978RB-I00 (Ministerio de Ciencia e Innovacion) (JMGG). MAT was supported by DPI2016-80054-R (Programa Estatal de Promocion del Talento y su Empleabilidad en I+D +i). EFG was supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 844646. There was no additional external funding received for this study.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Objective comparison of methods to decode anomalous diffusion

  • Muñoz-Gil, Gorka
  • Volpe, Giovanni
  • Aghion, Erez
  • Argun, Aykut
  • Beom Hong, Chang
  • Bland, Tom
  • Bo, Stefano
  • Firbas, Nicolás
  • Garibo i Orts, Óscar
  • Gentili, Alessia
  • Huang, Zihan
  • Jeon, Jae-Hyung
  • Kabbech, Hélène
  • Kim, Yeongjin
  • Garcia March, Miguel Angel|||0000-0001-7092-838X
  • Conejero, J. Alberto|||0000-0003-3681-7533
[EN] Deviations from Brownian motion leading to anomalous diffusion are found in transport dynamics from quantum physics to life sciences. The characterization of anomalous diffusion from the measurement of an individual trajectory is a challenging task, which traditionally relies on calculating the trajectory mean squared displacement. However, this approach breaks down for cases of practical interest, e.g., short or noisy trajectories, heterogeneous behaviour, or non-ergodic processes. Recently, several new approaches have been proposed, mostly building on the ongoing machine-learning revolution. To perform an objective comparison of methods, we gathered the community and organized an open competition, the Anomalous Diffusion challenge (AnDi). Participating teams applied their algorithms to a commonly-defined dataset including diverse conditions. Although no single method performed best across all scenarios, machine-learning-based approaches achieved superior performance for all tasks. The discussion of the challenge results provides practical advice for users and a benchmark for developers. Deviations from Brownian motion leading to anomalous diffusion are ubiquitously found in transport dynamics but often difficult to characterize. Here the authors compare approaches for single trajectory analysis through an open competition, showing that machine learning methods outperform classical approaches., Open access funding provided by University of Gothenburg. The authors would like to thank: Paula Kowalek for the graphical illustrations; Matthias Weiss and Maria Garcia-Parajo for sharing experimental data; Daniel Adam for help with compiling the data of single-atom trajectories. G.M.-G., B.R., and M.L. acknowledge support from ERC AdG NOQIA, Agencia Estatal de Investigación "Severo Ochoa Center of Excellence CEX2019-000910-S, Plan National FIDEUA PID2019-106901GB-I00/10.13039/ 501100011033, FPI), Fundació Privada Cellex, Fundació Mir-Puig, and from Generalitat de Catalunya (AGAUR Grant No. 2017 SGR 1341, CERCA program, QuantumCAT U16- 011424, co-funded by ERDF Operational Program of Catalonia 2014-2020), MINECO-EU QUANTERA MAQS (funded by State Research Agency (AEI) PCI2019-111828-2/ 10.13039/501100011033), EU Horizon 2020 FET-OPEN OPTOLogic (Grant No 899794), and the National Science Centre, Poland-Symfonia Grant No. 2016/20/W/ST4/00314. Giov.V. and A.A. acknowledge funding from ERC StG ComplexSwimmers (Grant No. 677511) and from the Knut and Alice Wallenberg Foundation. M.A.G.-M. acknowledges funding from the Spanish Ministry of Education and Vocational Training (MEFP) through the Beatriz Galindo program 2018 (BEAGAL18/00203). R.M. acknowledges DFG grant ME 1535/12-1. Gior.V. and A.G. acknowledge sponsorship for this work by the U.S. Office of Naval Research Global (Award No. N62909-18-1-2170). Z.H. acknowledges funding from the Fundamental Research Funds for the Central Universities. J.-H.J. acknowledges NRF grants 2020R1A2C4002490 and 2017K1A1A2013241. T.B. acknowledges support by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001086), the UK Medical Research Council (FC001086), and the Wellcome Trust (FC001086), and thanks Nate Goehring for supervision and acquisition of funding. This research was funded in whole, or in part, by the Wellcome Trust (FC001086). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. J.A.C. acknowledges support from the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00). P.K, H.L.-O. and J.S. were funded by the Polish National Science Centre (NCN-DFG Beethoven Grant No. 2016/23/G/ST1/ 04083) and acknowledge the support by the Wroclaw Centre for Networking and Supercomputing (calculations were performed using their BEM computing cluster). S.T. acknowledges the Deutscher Akademischer Austauschdienst for PhD Scholarship (DAAD Program ID 57214224) and support in the form of a Sacker postdoctoral fellowship and funding from the Pikovski-Valazzi matching scholarship (Tel Aviv University). H.K. and I.S. acknowledge funding from the Dutch Research Council (NWO) through the GENOMETRACK project of the Building Blocks of Life research program (Project No. 737.016.014). C.M. acknowledges funding from FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación through the "Ramón y Cajal program 2015 (Grant No. RYC-2015-17896), and the "Programa Estatal de I+D+i Orientada a los Retos de la Sociedad (Grant No. BFU2017-85693-R); from the Generalitat de Catalunya (AGAUR Grant No. 2017SGR940). C.M. also acknowledges the support of NVIDIA Corporation with the donation of the Titan Xp GPU and funding from the PO FEDER of Catalonia 2014-2020 (project PECT Osona Transformació Social, Ref. 001-P-000382).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT

  • Álvarez-Torres, María del Mar
  • Balaña, Carmen
  • Puig, Josep
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Garcia-Gomez, Juan M
[EN] Despite the complete treatment with surgery, chemotherapy and radiotherapy, patients with glioblastoma have a devasting prognosis. Although the role of extending temozolomide treatment has been explored, the results are inconclusive. Recent evidence suggested that tumor vascularity may be a modulating factor in combination with methylation of O6-methylguanine-DNA methyltransferase (MGMT) promotor gene on the effect of temozolomide-based therapies, opening new possibilities for personalized treatments. Before proposing a prospective interventional clinical study, it is necessary to confirm the beneficial effect of the combined effect of MGMT methylation and moderate tumor vascularity, as well as the lack of benefit of temozolomide in patients with a highly vascular tumor.In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (MGMT) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and calculation of relative cerebral blood volume (rCBV), used to define moderate- and high-vascular groups, were performed with the automatic ONCOhabitats method. We assessed the previously proposed rCBV threshold (10.7) and the new calculated ones (9.1 and 9.8) to analyze the association with survival for different populations according to vascularity and MGMT methylation status. We found that patients included in the moderate-vascular group had longer survival when MGMT is methylated (significant median survival difference of 174 days, p = 0.0129*). However, we did not find significant differences depending on the MGMT methylation status for the high-vascular group (p = 0.9119). In addition, we investigated the combined correlation of MGMT methylation status and rCBV with the prognostic effect of the number of temozolomide cycles, and only significant results were found for the moderate-vascular group. In conclusion, there is a lack of benefit of extending temozolomide treatment for patients with high vascular glioblastomas, even presenting MGMT methylation. Preliminary results suggest that patients with moderate vascularity and methylated MGMT glioblastomas would benefit more from prolonged adjuvant chemotherapy., M.A-T was supported by DPI2016-80054-R (Programa Estatal de Promocion del Talento y su Empleabilidad en I+D+i). This work was partially supported by the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00). This study was partially funded by the Fundacio La Marato TV3 (665/C/2013) (http://www.ccma.cat/tv3/marato/projectes-financats/2012/231/ Accessed on 8th September 2021). (JMGG); H2020-SC1-2016-CNECT Project (No. 727560) (JMGG), and H2020-SC1-BHC-2018-2020 (No. 825750) (JMGG). EFG was supported by the European Unions Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 844646 and South-Eastern Norway Regional Health Authority Grant 2021057.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Exploring the Trade-Off between generalist and specialized Models: A center-based comparative analysis for glioblastoma segmentation

  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Ferri-Borredà, Pablo|||0000-0002-3083-1169
  • Montosa-Micó, Víctor
  • Gómez-Mahiques, María
  • López-Mateu, Carlos
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Martí, Pau
[EN] Introduction Inherent variations between inter-center data can undermine the robustness of segmentation models when applied at a specific center (dataset shift). We investigated whether specialized center-specific models are more effective compared to generalist models based on multi-center data, and how center-specific data could enhance the performance of generalist models within a particular center using a fine-tuning transfer learning approach. For this purpose, we studied the dataset shift at center level and conducted a comparative analysis to assess the impact of data source on glioblastoma segmentation models. Methods & Materials The three key components of dataset shift were studied: prior probability shift¿variations in tumor size or tissue distribution among centers; covariate shift¿inter-center MRI alterations; and concept shift¿different criteria for tumor segmentation. BraTS 2021 dataset was used, which includes 1251 cases from 23 centers. Thereafter, 155 deep-learning models were developed and compared, including 1) generalist models trained with multi-center data, 2) specialized models using only center-specific data, and 3) fine-tuned generalist models using center-specific data. Results The three key components of dataset shift were characterized. The amount of covariate shift was substantial, indicating large variations in MR imaging between different centers. Glioblastoma segmentation models tend to perform best when using data from the application center. Generalist models, trained with over 700 samples, achieved a median Dice score of 88.98%. Specialized models surpassed this with 200 cases, while fine-tuned models outperformed with 50 cases. Conclusions The influence of dataset shift on model performance is evident. Fine-tuned and specialized models, utilizing data from the evaluated center, outperform generalist models, which rely on data from other centers. These approaches could encourage medical centers to develop customized models for their local use, enhancing the accuracy and reliability of glioblastoma segmentation in a context where dataset shift is inevitable., This work was funded by Grant PID2021-127110OA-I00 (PROGRESS) funded by MCIN/AEI/ 10.13039/501100011033 and by ERDF, SINUE (INNEST/2022/87 Agencia Valenciana de la Innovacion, Spain), ALBATROSS (PID2019-104978RB-I00) , Programa INVESTIGO (INVEST/2022/298) and Grant CIAICO/2022/064 (Lalaby-Glio) funded by Generalitat Valenciana, Spain.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

User-centred design of a clinical decision support system for palliative care: Insights from healthcare professionals

  • Blanes-Selva, Vicent|||0000-0002-0056-0329
  • Asensio-Cuesta, Sabina|||0000-0003-0246-3773
  • Garcia-Gomez, Juan M
  • Doñate-Martínez, Ascensión
  • Pereira Mesquita, Felipe
[EN] Objective:Although clinical decision support systems (CDSS) have many benefits for clinical practice, they also have several barriers to their acceptance by professionals. Our objective in this study was to design and validate The Aleph palliative care (PC) CDSS through a user-centred method, considering the predictions of the artificial intelligence (AI) core, usability and user experience (UX). Methods:We performed two rounds of individual evaluation sessions with potential users. Each session included a model evaluation, a task test and a usability and UX assessment. Results:The machine learning (ML) predictive models outperformed the participants in the three predictive tasks. System Usability Scale (SUS) reported 62.7 +/- 14.1 and 65 +/- 26.2 on a 100-point rating scale for both rounds, respectively, while User Experience Questionnaire - Short Version (UEQ-S) scores were 1.42 and 1.5 on the -3 to 3 scale. Conclusions:The think-aloud method and including the UX dimension helped us to identify most of the workflow implementation issues. The system has good UX hedonic qualities; participants were interested in the tool and responded positively to it. Performance regarding usability was modest but acceptable., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the InAdvance project (H2020-SC1-BHC-2018¿2020 grant number 825750) and the CANCERLESS project (H2020-SC1-2020-Single-Stage-RTD grant number 965351), both funded by the European Union¿s Horizon 2020 research and innovation programme. Also, it was partially supported by the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017¿ 2020, grant number PID2019-104978RB-I00)